The Global Lyme Disease Testing Market Forecast to 2033 released by Emergen Research delivers a comprehensive and detailed understanding of the industry, offering valuable insights for investors, stakeholders, and business strategists. The report highlights key market trends, growth potential, and strategic opportunities that are expected to shape the future of the Lyme Disease Testing market during the forecast period from 2025 to 2035.

The global Lyme Disease Testing market size is expected to grow from USD 11.5 billion by the end of 2025 to USD 24.6 billion by 2033, registering a revenue CAGR of 8.80% during the forecast period. The major Lyme Disease Testing market growth factors are rising adoption of at-home test kits, growth in point-of-care testing, and integration of artificial intelligence (AI).

The increasing prevalence of Lyme disease worldwide, particularly in North America and Europe, where tick populations are expanding due to climate change and deforestation is propelling the market growth. According to the European Commission's response to Petition No 0986/2025 in March 2025, the crucial role of diagnostic laboratories in Lyme disease testing was emphasized.

As more people engage in outdoor activities, the risk of tick bites and infections rises, leading to a higher demand for accurate diagnostic tests. Additionally, growing awareness about the long-term health complications of untreated Lyme disease, including neurological and cardiovascular issues, is driving patients and healthcare providers to prioritize early detection through reliable testing methods such as ELISA, Western blot, and PCR-based assays. According to the enters for Disease Control and Prevention (CDC), the growing prevalence of Lyme disease prompted significant initiatives for improved diagnostics, with around 476,000 Americans diagnosed annually.

Moreover, advancements in diagnostic technology are fueling market growth, with new, more sensitive, and rapid testing solutions emerging. Government initiatives and funding for Lyme disease research, coupled with the increasing adoption of point-of-care testing, are further expanding the market. The rise of telemedicine and at-home testing kits is also contributing to market expansion, as consumers seek convenient and accessible diagnostic options. With continued research and investment, the Lyme disease testing market is expected to grow significantly in the coming years.

The report is designed to answer several critical questions that are essential for decision-making. It explores who the dominant players are in the Lyme Disease Testing market, which regions are expected to witness the highest growth, and what consumer trends are likely to influence demand. Additionally, it examines the key growth drivers and restraining factors that may impact the market over the coming years.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-free-sample/4547

A key highlight of the research is its detailed segmentation of the market. The Lyme Disease Testing market is categorized based on product types, applications, end-user industries, and geographical regions. This segmentation provides a clear understanding of how different segments contribute to overall market performance and helps businesses identify high-growth opportunities.

Market competition in the Lyme Disease Testing industry is characterized by the presence of global and regional players such as Bio-Rad Laboratories, Quest Diagnostics, DiaSorin, and Thermo Fisher Scientific dominate the market with their strong product portfolios and global reach. Emerging startups and biotech firms are investing in novel diagnostic methods, including molecular and AI-driven approaches, to gain a competitive edge.

Mergers, acquisitions, and collaborations between diagnostic companies and healthcare providers are also shaping the market landscape. Continuous research funding and regulatory approvals for innovative Lyme disease testing solutions further intensify competition.

In January 2025, DiaSorin announced that it submitted the LIAISON LymeDetect test to the U.S. FDA in December 2025. Developed in partnership with QIAGEN, this test detects IgG, IgM, and T-cell mediated responses using QIAGEN’s proprietary QuantiFERON technology, an Interferon-Gamma Release Assay (IGRA). This novel solution will enhance DiaSorin's LIAISON immunodiagnostic offerings in the U.S. market, representing a significant milestone in its collaboration with QIAGEN.

Some of the key companies in the global Lyme Disease Testing Market include:

• DiaSorin S.p.A
• BIOMÉRIEUX
• Oxford Immunotec
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific, Inc.
• T2 Biosystems
• IGeneX
• Gold Standard Diagnostics
• ZEUS Scientific
• Trinity Biotech

Another important aspect covered in the report is the regional landscape. The study provides detailed insights into key regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Each region is analyzed in terms of regulatory frameworks, market trends, supply-demand dynamics, and the presence of major industry players. This helps businesses understand regional opportunities and plan their expansion strategies accordingly.

Competitive landscape:-

The report also places strong emphasis on the competitive landscape, offering a detailed analysis of the major companies operating in the Lyme Disease Testing market. It includes information about market share, product portfolios, pricing strategies, and key business developments. Strategic initiatives such as mergers and acquisitions, collaborations, joint ventures, partnerships, and product launches are thoroughly examined to provide a clear picture of the competitive environment.

Advancements in diagnostic technologies drives market growth

Advancements in diagnostic technologies are significantly boosting the Lyme disease testing market by improving the accuracy, speed, and reliability of test results. Traditional methods like ELISA and Western blot are being enhanced with molecular diagnostics such as PCR and next-generation sequencing (NGS), which offer higher sensitivity and earlier detection of the disease.

These innovations help reduce false negatives, a common challenge in Lyme disease testing, enabling timely treatment and better patient outcomes. Additionally, rapid point-of-care testing and at-home diagnostic kits are making it easier for individuals to access testing, driving demand in both clinical and direct-to-consumer segments. The World Health Organization (WHO) noted that Lyme disease is endemic in over 80 countries, underscoring its global impact.

The integration of artificial intelligence (AI) and machine learning in diagnostic tools is further propelling market growth by enabling more precise interpretation of test results. AI-driven algorithms can analyze complex biomarkers and identify Lyme disease cases with greater efficiency, improving diagnostic confidence.

Furthermore, advances in biosensors and lab-on-a-chip technology are leading to portable, cost-effective, and user-friendly testing solutions. As healthcare providers and research institutions continue to invest in cutting-edge diagnostics, the Lyme disease testing market is expected to expand, meeting the rising demand for faster and more accurate disease detection.

In addition to competitive analysis, the report evaluates how companies are responding to external challenges, particularly the impact of the COVID-19 pandemic. The pandemic has significantly affected global markets, including the Lyme Disease Testing industry, due to lockdowns, supply chain disruptions, and changing consumer demand. The report provides a comprehensive analysis of these impacts and outlines strategies adopted by companies to mitigate risks and sustain growth.

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/lyme-disease-testing-market

Another valuable feature of the study is its focus on advanced analytical insights. The report includes evaluations of supply-demand ratios, production and consumption volumes, and import/export dynamics. It also examines factors such as technological advancements, pricing trends, and industry-specific challenges, helping businesses gain a deeper understanding of the market.

Furthermore, the report offers strategic recommendations for both existing players and new entrants. These insights are designed to help businesses strengthen their market position, explore new opportunities, and develop effective expansion plans. The inclusion of industrial chain analysis and future market trends further enhances the value of the research.

The content is structured in a user-friendly manner, ensuring that complex data is presented clearly and logically. This makes it easier for readers to interpret information and apply it to their business strategies.

Emergen Research also provides customization options, allowing businesses to tailor the report according to their specific requirements. This ensures that organizations receive insights that are directly relevant to their goals and challenges.

Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/4547

In conclusion, the Global Lyme Disease Testing Market Report serves as a powerful tool for understanding market dynamics, identifying growth opportunities, and developing effective strategies. By combining detailed analysis, accurate forecasts, and actionable insights, Emergen Research continues to support businesses in navigating complex market environments.

About Emergen Research
Emergen Research is a leading market research and consulting company that provides syndicated reports, customized research solutions, and strategic consulting services. The company focuses on delivering accurate, data-driven insights that help clients understand market trends, analyze consumer behavior, and achieve sustainable growth.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: https://www.emergenresearch.com/

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com